Literature DB >> 23990311

Febrile neutropenia in hematologic malignancies.

Michael K Keng1, Mikkael A Sekeres.   

Abstract

Febrile neutropenia (FN) can occur at any time during the course of a malignancy, especially hematologic malignancies, from diagnosis to end-stage disease. The majority of FN episodes are typically confined to the period of initial diagnosis and active treatment. Because of suppressed inflammatory responses, fever is often the sole sign of infection. As FN is a true medical emergency, prompt identification of and intervention in FN can prolong survival and improve quality of life. This article reviews FN in the setting of hematologic malignancies, specifically myelodysplastic syndromes and acute leukemias, providing an overview of the definition of fever and neutropenia, diagnostic approach, categories of risk/risk assessment, management in patients at low and high risk, and prophylaxis of infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990311     DOI: 10.1007/s11899-013-0171-4

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  70 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 2.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Authors:  Eyal Robenshtok; Anat Gafter-Gvili; Elad Goldberg; Miriam Weinberger; Moshe Yeshurun; Leonard Leibovici; Mical Paul
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

Review 3.  Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis.

Authors:  T Berghmans; M Paesmans; J J Lafitte; C Mascaux; A P Meert; C Jacquy; A Burniat; E Steels; F Vallot; J P Sculier
Journal:  Support Care Cancer       Date:  2001-11-23       Impact factor: 3.603

4.  Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

Authors:  Marianne Paesmans; Jean Klastersky; Johan Maertens; Aspasia Georgala; Frédérique Muanza; Mickael Aoun; Augustin Ferrant; Bernardo Rapoport; Ken Rolston; Lieveke Ameye
Journal:  Support Care Cancer       Date:  2010-07-02       Impact factor: 3.603

5.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 7.  Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely.

Authors:  Eric J Bow
Journal:  J Natl Compr Canc Netw       Date:  2004-09       Impact factor: 11.908

Review 8.  Diagnosis and management of infectious complications in critically ill patients with cancer.

Authors:  Raghukumar Thirumala; Madhusudanan Ramaswamy; Sanjay Chawla
Journal:  Crit Care Clin       Date:  2010-01       Impact factor: 3.598

9.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.

Authors:  Axel Glasmacher; Archibald Prentice; Marcus Gorschlüter; Steffen Engelhart; Corinna Hahn; Benjamin Djulbegovic; Ingo G H Schmidt-Wolf
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy.

Authors:  I Ray-Coquard; C Borg; Th Bachelot; C Sebban; I Philip; G Clapisson; A Le Cesne; P Biron; F Chauvin; J Y Blay
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

View more
  13 in total

1.  Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.

Authors:  Lisa M Daniels; Urshila Durani; Jason N Barreto; John C O'Horo; Mustaqeem A Siddiqui; John G Park; Pritish K Tosh
Journal:  Support Care Cancer       Date:  2019-02-25       Impact factor: 3.603

2.  Disseminated mucormycosis: A sinister cause of neutropenic fever syndrome.

Authors:  Ghazal Tansir; Neha Rastogi; Prashant Ramteke; Prabhat Kumar; Manish Soneja; Ashutosh Biswas; Sanchit Kumar; Pankaj Jorwal; Upendra Baitha
Journal:  Intractable Rare Dis Res       Date:  2017-11

3.  The Value of Metagenomic Next-Generation Sequencing in Hematological Malignancy Patients with Febrile Neutropenia After Empiric Antibiotic Treatment Failure.

Authors:  Meng Zhang; Zhao Wang; Jiaxi Wang; Hairong Lv; Xia Xiao; Wenyi Lu; Xin Jin; Juanxia Meng; Yedi Pu; MingFeng Zhao
Journal:  Infect Drug Resist       Date:  2022-07-07       Impact factor: 4.177

4.  What is the role of leukopenia in the assessment of septic arthritis?

Authors:  Chelsea R Brown; Richard Samade; Daniel Lynch; John Mickley; Karilyn T M Larkin; Amy L Speeckaert
Journal:  J Orthop       Date:  2022-05-07

5.  Hypogammaglobulinemia in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

Authors:  Cassandra S Lange; April Rahrig; Sandra K Althouse; Robert P Nelson; Sandeep Batra
Journal:  J Adolesc Young Adult Oncol       Date:  2020-07-13       Impact factor: 1.757

Review 6.  Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.

Authors:  Paola Villafuerte-Gutierrez; Lucia Villalon; Juan E Losa; Cesar Henriquez-Camacho
Journal:  Adv Hematol       Date:  2014-11-27

7.  History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Authors:  Emmanuel Andrès; Rachel Mourot-Cottet; Frédéric Maloisel; Olivier Keller; Thomas Vogel; François Séverac; Martine Tebacher; Jacques-Eric Gottenberg; Jean-Christophe Weber; Georges Kaltenbach; Bernard Goichot; Jean Sibilia; Anne-Sophie Korganow; Raoul Herbrecht
Journal:  J Clin Med       Date:  2017-09-26       Impact factor: 4.241

Review 8.  A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.

Authors:  Na He; Fei Dong; Wei Liu; Suodi Zhai
Journal:  Infect Drug Resist       Date:  2020-06-16       Impact factor: 4.003

9.  Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience.

Authors:  Klára Piukovics; Gabriella Terhes; Andrea Lázár; Flóra Tímár; Zita Borbényi; Edit Urbán
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-09-18

10.  Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases.

Authors:  Josefine Nordvig; Theis Aagaard; Gedske Daugaard; Peter Brown; Henrik Sengeløv; Jens Lundgren; Marie Helleberg
Journal:  Open Forum Infect Dis       Date:  2018-10-25       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.